Core Viewpoint - The company plans to repurchase up to RMB 100 million worth of H-shares in the open market, reflecting confidence in its intrinsic value and growth potential [1] Group 1: Share Repurchase Plan - The board has resolved to use up to RMB 100 million to repurchase approximately 10.9097 million H-shares from the date of this announcement until the expiration of the repurchase authorization [1] - The actual repurchase price for each H-share will not exceed a premium of 5% over the average closing price of the H-shares for the five trading days preceding each repurchase [1] - Shares repurchased may be canceled, held as treasury shares, or used for share incentive plans [1] Group 2: Financial Health and Market Confidence - The company currently has a robust cash flow and stable overall financial condition, which can support its ongoing business development needs [1] - The board believes that the current trading price of the shares does not adequately reflect the company's intrinsic value and business prospects [1] - The share repurchase is seen as a demonstration of the company's and management's confidence in its business development and growth potential, ultimately benefiting the company and creating value for shareholders [1]
九源基因拟斥资最多1亿元回购股份